Life Cycle Investment Partners Ltd bought a new position in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 83,778 shares of the semiconductor company’s stock, valued at approximately $39,352,000.
Other large investors have also recently added to or reduced their stakes in the company. Empirical Asset Management LLC acquired a new position in Synopsys in the third quarter valued at approximately $773,000. Strategic Advisors LLC lifted its stake in Synopsys by 76.3% during the third quarter. Strategic Advisors LLC now owns 7,578 shares of the semiconductor company’s stock worth $3,739,000 after purchasing an additional 3,279 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Synopsys by 31.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,810 shares of the semiconductor company’s stock worth $6,957,000 after purchasing an additional 3,575 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Synopsys by 57.7% during the third quarter. Principal Financial Group Inc. now owns 412,766 shares of the semiconductor company’s stock worth $203,654,000 after purchasing an additional 150,973 shares in the last quarter. Finally, SeaTown Holdings Pte. Ltd. lifted its stake in Synopsys by 55.9% during the fourth quarter. SeaTown Holdings Pte. Ltd. now owns 22,300 shares of the semiconductor company’s stock worth $10,475,000 after purchasing an additional 8,000 shares in the last quarter. 85.47% of the stock is currently owned by institutional investors and hedge funds.
Synopsys Stock Up 4.1%
Synopsys stock opened at $524.74 on Friday. Synopsys, Inc. has a twelve month low of $376.18 and a twelve month high of $651.73. The stock’s fifty day simple moving average is $451.00 and its 200-day simple moving average is $451.09. The company has a current ratio of 1.36, a quick ratio of 1.26 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $100.52 billion, a P/E ratio of 81.48, a P/E/G ratio of 4.29 and a beta of 1.25.
Wall Street Analyst Weigh In
A number of research firms have commented on SNPS. HSBC cut Synopsys from a “buy” rating to a “hold” rating and set a $455.00 price target on the stock. in a research note on Friday, February 20th. Needham & Company LLC restated a “buy” rating on shares of Synopsys in a research note on Thursday, February 26th. Rosenblatt Securities decreased their price target on Synopsys from $560.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Citigroup upped their price target on Synopsys from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Wells Fargo & Company upped their price target on Synopsys from $450.00 to $505.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $536.00.
Read Our Latest Analysis on SNPS
Synopsys Profile
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
See Also
- Five stocks we like better than Synopsys
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
